Ipsen

Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss
Clinical Trials Arena
Mon, 09/16/24 - 11:07 am
Ipsen
Carbometyx
clinical trials
prostate cancer
Ipsen builds again, licensing Day One glioma drug
Pharmaphorum
Thu, 07/25/24 - 11:10 am
Ipsen
glioma
brain cancer
Day One Biopharmaceuticals
Ojemda
Ipsen licences second ADC via $1B bet on Foreseen Bio asset
First Word Pharma
Thu, 07/11/24 - 11:22 am
Ipsen
antibody-drug conjugate
FS001
Forseen Biotechnology
FDA grants accelerated approval to Genfit and Ipsen's liver disease drug
Reuters
Mon, 06/10/24 - 06:02 pm
Genfit
Ipsen
FDA
Ocaliva
primary biliary cholangitis. liver disease
Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers
Fierce Biotech
Fri, 06/7/24 - 11:20 am
Ipsen
Marengo Therapeutics
cold tumors
T-cell engager
Gilead, Ipsen build the case for their PBC drugs at EASL
Pharmaphorum
Wed, 06/5/24 - 11:06 am
Gilead Sciences
Ipsen
primary biliary cholangitis
seladelpar
EASL
elafibranor
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
Fierce Biotech
Mon, 04/22/24 - 11:32 am
Ipsen
Skyhawk Therapeutics
RNA modulation
R&D
Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer
Fierce Biotech
Tue, 04/2/24 - 11:34 am
Ipsen
antibody-drug conjugate
Sutro BioPharma
With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer
Fierce Pharma
Tue, 02/13/24 - 11:12 pm
Ipsen
Onivyde
Nalirifox
pancreatic cancer
FDA
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
Pharmaphorum
Thu, 12/7/23 - 11:01 am
Genfit
Ipsen
elafibranor
primary biliary cholangitis
FDA
priority review
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Mon, 08/21/23 - 10:02 am
Exelixis
Ipsen
Carbometyx
prostate cancer
FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease
BioSpace
Thu, 08/17/23 - 10:08 am
Ipsen
palovarotene
FDA
Sohonos
fibrodysplasia ossificans progressiva
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP
Globe Newswire
Wed, 06/28/23 - 10:27 pm
FDA
Ipsen
palovarotene
FOP
fibrodysplasia ossificans progressiva
FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm
BioSpace
Tue, 06/27/23 - 10:19 am
Ipsen
FDA
palovarotene
fibrodysplasia ossificans progressiva

Pages